Clinical Trials on DM2 in Australia

Total 8 results

Kyowa Kirin, Inc.

Recruiting

Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema

Diabetic Macular Edema (DME)

United States, Japan, Korea, Republic of, Australia
Bayer

Recruiting

The SPECTRUM Study: An Observational Study to Learn More About How Well Aflibercept 8 mg Works in Treating Visual Impairment Due to Neovascular Age-related Macular Degeneration or Diabetic Macula Edema

Visual Impairment | Neovascular Age-related Macular Degeneration (nAMD) | Diabetic Macula Edema (DME)

Germany, Canada, Denmark, France, Italy, Saudi Arabia, Switzerland, Australia, Finland, Netherlands, Sweden, Norway, United Arab Emirates, Japan, United Kingdom
Dyne Therapeutics

Recruiting

Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping (DELIVER)

Duchenne Muscular Dystrophy (DMD)

United States, Belgium, Canada, United Kingdom, Spain, Australia, Italy
Ascentage Pharma Group Inc.
Merck Sharp & Dohme LLC

Recruiting

A Study of APG-115 in Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors

Melanoma | P53 Mutation | Uveal Melanoma | Cutaneous Melanoma | Mucosal Melanoma | Malignant Peripheral Nerve Sheath Tumors | MPNST | Unresectable or Metastatic Melanoma or Advanced Solid Tumors | MDM2 Gene Mutation

United States, Australia
Santhera Pharmaceuticals

Terminated

A Phase III Double-blind Study With Idebenone in Patients With Duchenne Muscular Dystrophy (DMD) Taking Glucocorticoid Steroids (SIDEROS)

Duchenne Muscular Dystrophy (DMD)

United States, Spain, Netherlands, Sweden, Germany, France, Belgium, United Kingdom, Italy, Ireland, Switzerland, Austria, Bulgaria, Hungary, Israel
Genzyme, a Sanofi Company

Completed

ATHENA: Natural History of Disease Study in Alport Syndrome Patients (RG012-01)

Alport Syndrome Patients With eGFR Between 45-90 ml/Min/1.73 m2

France, Germany, Australia, United States, United Kingdom, Canada
National Cancer Institute (NCI)

Completed

Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic Leukemia With Maturation (M2) | Adult Acute Myeloblastic Leukemia Without Maturation (M1) | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities and other conditions

United States, Canada, Australia
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes

Secondary Acute Myeloid Leukemia | Childhood Acute Erythroleukemia (M6) | Childhood Acute Megakaryocytic Leukemia (M7) | Childhood Acute Monoblastic Leukemia (M5a) | Childhood Acute Monocytic Leukemia (M5b) | Childhood Acute Myeloblastic Leukemia With Maturation (M2) | Childhood Acute Myeloblastic... and other conditions

United States, Canada, Australia, Puerto Rico

Clinical Trials on DM2 in Australia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bahrain

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations